Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel
NASDAQ:RGEN

Repligen Q3 2026 Earnings Date & Estimates

Repligen logo
$175.42 +2.91 (+1.69%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$175.58 +0.16 (+0.09%)
As of 10/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Repligen is estimated to report Q3 2026 earnings on Tuesday, October 27, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Repligen in Q3 2026

Repligen is expected to post earnings of $0.46 per share on revenue of $206.73 million. In the same quarter a year earlier Repligen reported $0.46 per share on revenue of $188.81 million. Repligen last reported on July 28, 2026, posting $0.54 per share and beating the $0.4470 consensus estimate. Repligen has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.46
Expected Revenue
$206.73 million
Prior-Year EPS
$0.46
Prior-Year Revenue
$188.81 million
Expected EPS Growth
0.0%
Expected Revenue Growth
+9.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.54 (Beat by +$0.0930)
Last Quarter Revenue
$204.13 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Repligen Q3 2026 Earnings FAQ

Repligen (NASDAQ:RGEN) is estimated to report Q3 2026 earnings on Tuesday, October 27, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Repligen's Q3 2026 earnings conference call is scheduled for Tuesday, October 27, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Repligen to post earnings of $0.46 per share for Q3 2026.

The consensus revenue estimate for Repligen is $206.73 million for Q3 2026.

Repligen Earnings Headlines

Repligen to Report Third Quarter 2026 Financial Results
October 13 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379563/24603/en/repligen-to-report-third-quarter-2026-financial-results.html
Repligen Corp Completes Acquisition Of BioLife Solutions
October 7, 2026  |  rttnews.comhttps://www.rttnews.com/3697110/repligen-corp-completes-acquisition-of-biolife-solutions.aspx
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.tc pixel
October 14 at 1:00 AM  |  Behind the Markets (Ad)
Repligen Falls as Investors Digest BioLife Solutions Deal Closing
October 6, 2026  |  quiverquant.comQ
Repligen Completes BioLife Acquisition to Expand Cell Therapies
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/repligen-completes-biolife-acquisition-to-expand-cell-therapies?utm_source=marketbeat.com&utm_medium=referral
BioLife Solutions Completes Repligen Merger and Nasdaq Delisting
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/biolife-solutions-completes-repligen-merger-and-nasdaq-delisting?utm_source=marketbeat.com&utm_medium=referral
See More Repligen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Repligen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Repligen and other key companies, straight to your email.

About Repligen

Repligen (NASDAQ:RGEN) (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment. These solutions are designed to support purification, separation, monitoring and efficient handling of biological materials while helping biopharmaceutical producers improve manufacturing processes.

Founded in 1981, Repligen is headquartered in Waltham, Massachusetts, and serves biopharmaceutical and life sciences customers internationally. The company has expanded its offerings through internal development and acquisitions, including businesses focused on filtration, chromatography, single-use systems and process analytics. Tony J. Hunt has served as Repligen’s president and chief executive officer since 2015.

View Repligen Profile
Earnings Tools